JP2010540661A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010540661A5 JP2010540661A5 JP2010528172A JP2010528172A JP2010540661A5 JP 2010540661 A5 JP2010540661 A5 JP 2010540661A5 JP 2010528172 A JP2010528172 A JP 2010528172A JP 2010528172 A JP2010528172 A JP 2010528172A JP 2010540661 A5 JP2010540661 A5 JP 2010540661A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- enantiomerically enriched
- group
- nilvadipine
- condition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims 7
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims 7
- 241001465754 Metazoa Species 0.000 claims 7
- 230000003942 amyloidogenic effect Effects 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 229960005366 nilvadipine Drugs 0.000 claims 7
- 230000036772 blood pressure Effects 0.000 claims 5
- 210000004556 brain Anatomy 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 4
- 206010029350 Neurotoxicity Diseases 0.000 claims 2
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 230000006933 amyloid-beta aggregation Effects 0.000 claims 2
- 230000003796 beauty Effects 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 239000003889 eye drop Substances 0.000 claims 2
- 229940012356 eye drops Drugs 0.000 claims 2
- 239000007937 lozenge Substances 0.000 claims 2
- 230000007388 microgliosis Effects 0.000 claims 2
- 230000007135 neurotoxicity Effects 0.000 claims 2
- 231100000228 neurotoxicity Toxicity 0.000 claims 2
- -1 sachets Substances 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 241000238367 Mya arenaria Species 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 210000005252 bulbus oculi Anatomy 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 230000001631 hypertensive effect Effects 0.000 claims 1
- 208000021822 hypotensive Diseases 0.000 claims 1
- 230000001077 hypotensive effect Effects 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000007914 intraventricular administration Methods 0.000 claims 1
- 231100000682 maximum tolerated dose Toxicity 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 235000012431 wafers Nutrition 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97795307P | 2007-10-05 | 2007-10-05 | |
| US60/977,953 | 2007-10-05 | ||
| US4610908P | 2008-04-18 | 2008-04-18 | |
| US61/046,109 | 2008-04-18 | ||
| PCT/US2008/078786 WO2009046323A1 (en) | 2007-10-05 | 2008-10-03 | Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010540661A JP2010540661A (ja) | 2010-12-24 |
| JP2010540661A5 true JP2010540661A5 (https=) | 2011-11-17 |
| JP5411145B2 JP5411145B2 (ja) | 2014-02-12 |
Family
ID=40523447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010528172A Expired - Fee Related JP5411145B2 (ja) | 2007-10-05 | 2008-10-03 | （−）−ニルバジピンエナンチオマーによってアミロイド沈着、アミロイド神経毒性、およびミクログリオーシスを減少させる方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8236346B2 (https=) |
| EP (1) | EP2214666B1 (https=) |
| JP (1) | JP5411145B2 (https=) |
| KR (1) | KR101417200B1 (https=) |
| CN (1) | CN101883564B (https=) |
| AU (1) | AU2008308519B2 (https=) |
| BR (1) | BRPI0817516A2 (https=) |
| CA (1) | CA2701620C (https=) |
| DK (1) | DK2214666T3 (https=) |
| ES (1) | ES2449594T3 (https=) |
| MX (1) | MX2010003669A (https=) |
| NZ (1) | NZ584729A (https=) |
| PL (1) | PL2214666T3 (https=) |
| RU (1) | RU2490014C2 (https=) |
| TW (1) | TWI500422B (https=) |
| WO (1) | WO2009046323A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140286910A1 (en) * | 2013-03-19 | 2014-09-25 | Nikolai Tankovich | Stem cells and methods incorporating environmental factors as a means for enhancing stem cell proliferation and plasticity |
| CN112826794B (zh) | 2019-11-06 | 2022-02-11 | 上海交通大学医学院 | 一种靶向修复神经血管病变的纳米复合物及其制备与应用 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4338322A (en) * | 1975-07-02 | 1982-07-06 | Fujisawa Pharmaceutical Co., Ltd. | 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same |
| JPS6038322A (ja) * | 1983-08-11 | 1985-02-27 | Fujisawa Pharmaceut Co Ltd | ジヒドロピリジンａ物質含有易溶性固形製剤 |
| JPS61129140A (ja) | 1984-11-27 | 1986-06-17 | Nitto Electric Ind Co Ltd | 医薬組成物 |
| GB8431119D0 (en) * | 1984-12-10 | 1985-01-16 | Fujisawa Pharmaceutical Co | Anti-arteriosclerotic composition |
| US4940556A (en) | 1986-01-30 | 1990-07-10 | Syntex (U.S.A.) Inc. | Method of preparing long acting formulation |
| US4992445A (en) * | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5114946A (en) * | 1987-06-12 | 1992-05-19 | American Cyanamid Company | Transdermal delivery of pharmaceuticals |
| US5001139A (en) * | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| EP0294601B1 (en) | 1987-06-12 | 1993-01-20 | American Cyanamid Company | Transdermal delivery of pharmaceuticals |
| US5045553A (en) * | 1987-06-24 | 1991-09-03 | Fujisawa Pharmaceutical Company, Ltd. | Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter |
| US4820720A (en) * | 1987-08-24 | 1989-04-11 | Alza Corporation | Transdermal drug composition with dual permeation enhancers |
| US5508413A (en) * | 1987-08-27 | 1996-04-16 | Fujisawa Pharmaceutical Co., Ltd. | (+)-5-isopropyl 3-methyl 2-cyano-6 methyl-4-(3-nitrophenyl)-1, 4-dihydropyridine-3, 5-dicarboxylate |
| ATE76292T1 (de) | 1987-11-25 | 1992-06-15 | American Cyanamid Co | System fuer die verzoegerte (kontrollierte) freisetzung von substituierten dihydropyridincalciumantagonisten. |
| US5160734A (en) * | 1987-11-25 | 1992-11-03 | American Cyanamid Company | Sustained release delivery system for substituted dihydropyridine calcium channel blockers |
| US4902514A (en) * | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| JP2718105B2 (ja) | 1988-10-27 | 1998-02-25 | 藤沢薬品工業株式会社 | （＋）−２−シアノ−６−メチル−４−（３−ニトロフェニル）−１，４−ジヒドロピリジン−３，５−ジカルボン酸５−イソプロピル３−メチルの光安定性結晶 |
| WO1990011761A1 (en) * | 1989-03-31 | 1990-10-18 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
| JPH0381262A (ja) | 1989-08-23 | 1991-04-05 | Yamanouchi Pharmaceut Co Ltd | ジヒドロピリジン系カルシウム拮抗薬の光学活性体の製造法 |
| JP2867462B2 (ja) | 1989-09-12 | 1999-03-08 | 藤沢薬品工業株式会社 | 経皮吸収用製剤 |
| JP2920956B2 (ja) | 1989-10-06 | 1999-07-19 | 藤沢薬品工業株式会社 | ニルバジピン含有持続性錠剤 |
| US5258393A (en) * | 1990-02-21 | 1993-11-02 | Fujisawa Pharmaceutical Co., Ltd. | Use of a dihydropyridine compound for improving inner ear microcirculation |
| JPH06500554A (ja) | 1990-08-23 | 1994-01-20 | ザ・チルドレンズ・メディカル・センター・コーポレイション | エイズ性痴呆、脊髄障害、末梢神経障害、および視覚喪失の治療 |
| WO1993005770A1 (fr) | 1991-09-20 | 1993-04-01 | Fujisawa Pharmaceutical Co., Ltd. | Preparation a longue duree d'action |
| JPH05139974A (ja) | 1991-11-26 | 1993-06-08 | Fujisawa Pharmaceut Co Ltd | ジヒドロピリジンａ物質含有易溶性固体分散体の製造法 |
| US5834496A (en) * | 1991-12-02 | 1998-11-10 | Sepracor, Inc. | Methods for treating hypertension using optically pure S(-) felodipine |
| DE4141646A1 (de) | 1991-12-17 | 1993-06-24 | Klinge Co Chem Pharm Fab | Arzneimittelkombination mit synergistischer wirkung, verfahren zu seiner herstellung und seine verwendung |
| US5340591A (en) * | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| DE4229805A1 (de) | 1992-09-07 | 1994-03-24 | Werner E G Prof Dr Mueller | Kalzium-Kanal-Antagonisten oder deren Derivate zur Herstellung eines Arzneimittels zur Bekämpfung von Erkrankungen, die durch Prion-Proteine oder Prion-analoge Proteine ausgelöst werden |
| US5721263A (en) * | 1993-06-07 | 1998-02-24 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for angiotensin II-mediated diseases |
| CA2125251C (en) | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | A pharmaceutical composition for angiotensin ii-mediated diseases |
| AU682192B2 (en) * | 1993-06-30 | 1997-09-25 | Fujisawa Pharmaceutical Co., Ltd. | Encapsulated medicine |
| US6334997B1 (en) * | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| EP0911027A4 (en) * | 1996-04-26 | 2000-11-29 | Fujisawa Pharmaceutical Co | THE DIHYDROPYRIDINE CONTAINS TO IMPROVE THE CIRCULATION OF THE EYE-SURROUNDING TISSUE |
| US6271259B1 (en) * | 1996-05-07 | 2001-08-07 | Ito En, Ltd. | Method for improving the brain function, inhibiting glutamate excitotoxicity and rescuing from neuronal death |
| KR100222306B1 (ko) | 1996-11-20 | 1999-10-01 | 이병언 | 닐바디핀 속효성 고형제제 및 이의 제조방법 |
| US6541479B1 (en) * | 1997-12-02 | 2003-04-01 | Massachusetts College Of Pharmacy | Calcium channel blockers |
| JP2002517440A (ja) | 1998-06-08 | 2002-06-18 | アドバンスド メディスン インコーポレーテッド | 新規カルシウムチャンネル薬物および用途 |
| CA2319142A1 (en) * | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Novel therapeutic agents for membrane transporters |
| NZ509260A (en) | 1998-07-10 | 2003-09-26 | Novartis Ag | Pharmaceutical composition containing valsartan and a calcium channel blocker |
| WO2001064250A1 (en) | 2000-03-03 | 2001-09-07 | Fujisawa Pharmaceutical Co., Ltd. | Remedies for malignant tumor-concomitant neurosis and azoor or analogous diseases thereof |
| ES2287110T3 (es) | 2000-04-11 | 2007-12-16 | Sankyo Company, Limited | Composicion farmaceutica estabilizada que contiene un bloqueador de calcio consistente en azelnidipina. |
| JP2001335483A (ja) | 2000-05-30 | 2001-12-04 | Nichiko Pharmaceutical Co Ltd | ニルバジピン含有製剤 |
| AU2001278045B2 (en) * | 2000-07-27 | 2006-08-03 | Pharmacia Corporation | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure |
| JP3968687B2 (ja) | 2000-09-13 | 2007-08-29 | 東和薬品株式会社 | 易吸収性ニルバジピン錠 |
| JP3470096B2 (ja) | 2000-09-19 | 2003-11-25 | 沢井製薬株式会社 | ニルバジピン含有易溶性固形製剤およびその製造法 |
| EP1343506A1 (de) * | 2000-12-19 | 2003-09-17 | MERCK PATENT GmbH | Pharmazeutische formulierung enthaltend pyrazolo 4,3-d]pyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate |
| US20040072846A1 (en) * | 2000-12-19 | 2004-04-15 | Hans-Michael Eggenweiler | Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives |
| US7083642B2 (en) * | 2000-12-22 | 2006-08-01 | Avantec Vascular Corporation | Delivery of therapeutic capable agents |
| CA2333494A1 (en) | 2001-02-01 | 2002-08-01 | Vasogen Ireland Limited | Blood brain barrier modulation |
| ES2275007T3 (es) | 2001-05-25 | 2007-06-01 | Schering Corporation | Uso de derivados de azetidinona sustitudos en el tratamiento de la enfermedad de alzeimer. |
| EP1426051B1 (en) * | 2001-09-11 | 2008-07-16 | Asahi Kasei Pharma Corporation | Medicinal composition for prevention of or treatment for cerebrovascular disorder |
| EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| WO2004034963A2 (en) | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| DK1507558T3 (da) | 2002-05-17 | 2011-12-05 | Novartis Pharma Ag | Farmaceutisk sammensætning omfattende en renininhibitor, en calciumkanalblokker og et diuretikum |
| PE20040468A1 (es) | 2002-05-17 | 2004-09-14 | Novartis Ag | Combinacion de compuestos organicos |
| JP2003146878A (ja) | 2002-11-22 | 2003-05-21 | Sawai Pharmaceutical Co Ltd | ニルバジピン含有易溶性固形製剤およびその製造法 |
| US20050031651A1 (en) * | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| EP1585520A1 (en) | 2002-12-24 | 2005-10-19 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| CA2525970C (en) * | 2003-05-15 | 2011-03-22 | Roskamp Research, Llc | Use of nilvadipine for reducing amyloid deposition, amyloid neurotoxicity and microgliosis |
| JP2004002460A (ja) | 2003-07-29 | 2004-01-08 | Towa Yakuhin Kk | 易吸収性ニルバジピン錠の製造法 |
| WO2009046338A1 (en) * | 2007-10-05 | 2009-04-09 | Roskamp Research Llc | Method for increasing cerebral blood flow with (+)-nilvadipine enantiomer |
-
2008
- 2008-10-03 TW TW097138351A patent/TWI500422B/zh not_active IP Right Cessation
- 2008-10-03 US US12/245,354 patent/US8236346B2/en not_active Expired - Fee Related
- 2008-10-03 KR KR1020107009874A patent/KR101417200B1/ko not_active Expired - Fee Related
- 2008-10-03 DK DK08836256.1T patent/DK2214666T3/da active
- 2008-10-03 BR BRPI0817516-0A patent/BRPI0817516A2/pt not_active Application Discontinuation
- 2008-10-03 ES ES08836256.1T patent/ES2449594T3/es active Active
- 2008-10-03 JP JP2010528172A patent/JP5411145B2/ja not_active Expired - Fee Related
- 2008-10-03 EP EP08836256.1A patent/EP2214666B1/en active Active
- 2008-10-03 NZ NZ584729A patent/NZ584729A/xx not_active IP Right Cessation
- 2008-10-03 MX MX2010003669A patent/MX2010003669A/es active IP Right Grant
- 2008-10-03 CA CA2701620A patent/CA2701620C/en not_active Expired - Fee Related
- 2008-10-03 AU AU2008308519A patent/AU2008308519B2/en not_active Ceased
- 2008-10-03 WO PCT/US2008/078786 patent/WO2009046323A1/en not_active Ceased
- 2008-10-03 RU RU2010117634/15A patent/RU2490014C2/ru active
- 2008-10-03 CN CN200880118761XA patent/CN101883564B/zh not_active Expired - Fee Related
- 2008-10-03 PL PL08836256T patent/PL2214666T3/pl unknown
-
2010
- 2010-02-01 US US12/697,436 patent/US8236347B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025024102A (ja) | 神経障害および神経障害の処置方法 | |
| JP7781768B2 (ja) | 神経学的および精神障害の治療方法 | |
| JP2010518122A5 (https=) | ||
| JP2013544887A5 (https=) | ||
| JP2013526544A5 (https=) | ||
| JP2014506321A5 (https=) | ||
| JP2015526458A5 (https=) | ||
| WO2017031319A1 (en) | Noradrenergic drug treatment of obstructive sleep apnea | |
| AU2019280980B2 (en) | Use of (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders | |
| JP2019532926A5 (https=) | ||
| JP2021525729A5 (https=) | ||
| ES2426008T5 (es) | Tratamiento de síntomas de la enfermedad de Parkinson con ligandos del receptor de histamina H3 de alquilaminas no imidazólicas | |
| JP2021512920A5 (https=) | ||
| FR2974729A1 (fr) | Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent | |
| JP2007506801A (ja) | モダフィニルおよび他の薬剤を含んでなる製薬学的組成物 | |
| US20170151222A1 (en) | Snoring treatment | |
| JP2010540661A5 (https=) | ||
| CN101272776B (zh) | 氨基甲酸酯在制备治疗物质滥用相关疾病药物中的用途 | |
| JP2011500589A5 (https=) | ||
| JP2013518061A5 (https=) | ||
| CA2525970A1 (en) | Use of nilvadipine for reducing amyloid deposition, amyloid neurotoxicity and microgliosis | |
| PT1628652E (pt) | Combinação do modafinil analéptico e um antidepressivo para o tratamento da depressão | |
| CN118787626A (zh) | 一种d-丝氨酸化合物在制备神经调节剂和治疗脑功能障碍药物中的应用 | |
| JP2005505570A (ja) | Ｐｄｅ阻害剤及びロイコトリエン受容体拮抗物質の複合薬 | |
| RU2009141168A (ru) | Способы и композиции, содержащие дезвенлафаксин или дулоксетин, для лечения расстройств дыхания во время сна |